Soley Therapeutics, founded by cardiologist Yerem Yeghiazarians, MD, and molecular cancer biologist Kurosh Ameri, PhD, aims to revolutionize drug discovery by integrating AI with cellular response detection. The company has developed a novel high-content phenotypic drug screening platform that visualizes drug effects on cells through molecular-microscopic images. This technology allows for multi-dimensional analysis of cellular responses, facilitating the development of more efficacious drugs. Soley Therapeutics primarily focuses on addressing complex diseases such as cancer and cardiovascular conditions.
Notable figures associated with Soley Therapeutics include its founders, Yerem Yeghiazarians and Kurosh Ameri, who bring extensive expertise in cardiology and molecular cancer biology. The company has garnered attention for its innovative approach to drug discovery, leveraging AI to decode cellular language at scale. Key achievements include the successful development of their high-content screening platform, which has the potential to significantly accelerate and enhance the drug development process. Soley Therapeutics is poised to make a substantial impact on the pharmaceutical industry by improving the efficiency and effectiveness of new drug discoveries.
Quick Facts
When was Soley Therapeutics' last funding round?
Soley Therapeutics' most recent funding round was for $200M (USD) in January 2026.
How much disclosed funding has Soley Therapeutics raised?
As of Jan 7, 2026, Soley Therapeutics has disclosed funding of $220M (USD).
